Ionis Pharmaceuticals, Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-06-30 was $20.26M, a 1475.27% increase year-over-year.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-03-31 was $57.30M, a 2455.84% increase year-over-year.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-12-31 was $107.82M, a 26720.15% increase year-over-year.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-09-30 was $81.26M, a 1060.51% increase year-over-year.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2025 was $192.60M, a 473.07% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2024 was $33.61M, a 32.02% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $49.44M, a 675.79% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $6.37M, a 44.89% decline from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $20.26M 10-Q · filed 2026-07-29 | $266.64M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $57.30M 10-Q · filed 2026-04-29 | $247.66M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $107.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $192.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $81.26M 10-Q · filed 2025-10-29 | $85.19M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $1.29M 10-Q · filed 2026-07-29 | $10.93M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $2.24M 10-Q · filed 2026-04-29 | $12.24M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.61M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.00M 10-Q · filed 2025-10-29 | $73.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.59M 10-Q · filed 2025-07-30 | $70.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $23.61M 10-Q · filed 2025-04-30 | $70.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $40.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.44M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.73M 10-Q · filed 2024-11-06 | $9.02M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $2.39M 10-Q · filed 2024-08-01 | $7.86M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $2.56M 10-Q · filed 2024-05-07 | $7.08M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $343.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $6.37M 10-K · filed 2025-02-19 |
| 2022-09-30 | $2.57M 10-Q · filed 2023-11-02 | $6.03M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $1.61M 10-Q · filed 2023-08-09 | $5.38M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $1.85M 10-Q · filed 2023-05-03 | $5.65M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $11.56M 10-K · filed 2024-02-21 |
| 2021-09-30 | $1.92M 10-Q · filed 2022-11-09 | $34.15M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $1.88M 10-Q · filed 2022-08-09 | $45.22M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $7.76M 10-Q · filed 2022-05-04 | $52.14M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $22.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $52.03M 10-K · filed 2023-02-22 |
| 2020-09-30 | $13.00M 10-Q · filed 2021-11-03 | $36.97M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $8.80M 10-Q · filed 2021-08-04 | $34.10M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $7.65M 10-Q · filed 2021-05-05 | $60.25M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $119.66M 10-K · filed 2022-02-25 |
| 2019-09-30 | $10.13M 10-Q · filed 2020-11-04 | $125.23M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $34.94M 10-Q · filed 2020-08-05 | $121.33M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $67.06M 10-Q · filed 2020-05-06 | $89.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $27.90M 10-K · filed 2021-02-24 |
| 2018-09-30 | $6.23M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $2.91M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $5.66M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $22.93M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $13.71M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $24.89M 10-K · filed 2018-02-28 | |
| 2014-12-31 | $23.07M 10-K · filed 2017-03-01 | |
| 2013-12-31 | $62.96M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $9.47M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $3.57M 10-K · filed 2014-03-03 | |
| 2010-12-31 | $4.36M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $13.16M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |